NEC OncoImmunity Acquires Neoantigen Vaccine Development Assets of VAXIMM | No more news
NEC OncoImmunity Acquires Neoantigen Vaccine Development Assets of VAXIMM Details Category: More news Posted on Tuesday, 08 March 2022 09:43 Hits: 33 VAXIMM technology enables the rapid generation and delivery of personalized T-cell cancer vaccines and can overcome key challenges faced by the neoantigen field NEC OncoImmunity willRead More →